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Introduction
Leishmaniasis owes its name to Sir William Leishman, a 
British army medical officer, who discovered the disease in 
1901 and published his findings in 1903 [28]. Leishmania-
sis is a polymorphic disease produced by several protozoa 
species of Leishmania genus that can affect the skin, mu-
cous or internal organelle. Infections in humans are caused 
by more than 20 species of Leishmania [27, 28]. Cutaneous 
leishmaniasis can be caused by several Leishmania spp and 
is transmitted to human beings and animals by sandflies 
[19, 20, 24, 27]. Other modes of transmission of leishmania-
sis to humans, though less common, include blood transfu-
sion, sharing of contaminated needles, and mother-to-child 
transmission during pregnancy [16, 17].  Risk factors in-
clude  poverty,  malnutrition,  deforestation, and  urbaniza-
tion [3, 27]. Some people have a silent infection, without any 
symptoms or signs. People who develop clinical evidence of 
infection have one or more sores on their skin. The sores can 
change in size and appearance over time [9]. Leishmaniasis 
has three principal clinical forms: cutaneous (CL), mucocu-
taneous (ML) and visceral (VL). The distributions are: ≈1.5 
million cases of CL and ≈50 000 cases of VL occur annually 
[11].   Cutaneous leishmaniasis (CL) is a neglected world-
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Abstract 
Background: Leishmaniasis is a disease caused by parasites of the Leishmania type.  Cutaneous leishmaniasis is a neglected worldwide, zoonotic, vector-
borne, tropical disease. The clinical spectrum of leishmaniasis ranges from a self-resolving cutaneous ulcer to a mutilating mucocutaneous disease and 
even to a lethal systemic illness. People who recover from cutaneous leishmaniasis are protected against future infections. The risk of infection is for 
people of all ages if they live or travel where leishmaniasis is found. Leishmaniasis usually is more common in rural than in urban areas, but it is found in 
the outskirts of some cities. The transmission risk is highest from dusk to dawn because this is when sand flies generally are the most active. Cutaneous 
leishmaniasis causes skin lesions, which can persist for months, sometimes years. The skin lesions usually develop within several weeks or months after the 
exposure but occasionally first appear years later.  Presented here is a clinical case of leishmaniasis of the cutaneous form, diagnosed by the microscopic 
method. The patient was diagnosed, monitored and treated in Clinical Hospital of Infectious Diseases “Toma Ciorbă” from 10.01.2018-09.02.2018. The 
progression of the disease was favorable following the etiotropic treatment with antimony meglumine (Glucantime), requiring careful monitoring due 
to adverse reactions.
Conclusions: Clinical symptomatology was characteristic for cutaneous leishmaniasis: skin lesions of various  pink-cherry sizes, some with ulcers on 
the body. The first etiotropic treatment with antimony meglumine was effective. Antimonate Meglumine treatment at a dose of 15 ml resulted in adverse 
reactions: asthenia, fever, myalgia and arthralgia.
Key words: cutaneous leishmaniasis, diagnosis, treatment, adverse reactions.
to public health. This threat may spread from endemic to 
non-endemic areas, is endemic in the tropics and neotropics 
[13, 20]. The World Health Organisation (WHO) estimates 
that 350 million people are at risk of contracting leishma-
niasis and an estimated 1.6 million new cases occur annu-
ally [23]. The morbidity associated with human CL is 0.7-1.2 
million cases distributed worldwide resulting in extensive 
integumentary lesions [1]. Since 2002, there has been a dra-
matic increase in the cases of cutaneous leishmaniasis: from 
1 case per 100,000 in 2002 to 4.5 cases per 100,000 in 2012. 
Since 2012, the incidence rates have decreased (2.7 cases per 
100,000 in 2015) [6].  
There are two groups of CL, New World and Old World 
leishmaniasis, with only the latter group identified in the 
Middle East and it includes three main species;  L.  ma-
jor, L.  tropica  and L.  infantum  [22]. The majority of cuta-
neous Leishmaniasis cases occur in Afghanistan, Algeria, 
Brazil, Colombia, the Islamic Republic of Iran, Pakistan, 
Peru, Saudi Arabia and the Syrian Arab Republic [1, 28].   
Recent studies showed a high prevalence of CL in Iran [7, 
8], Turkey and Syria [12]. Although Iraq shares long bor-
ders with these countries and leishmaniasis is endemic, the 
World Health Organization has not classified it as a country 
with a high burden profile [26]. CL has long been endemic 
in Israel. More recently, illness caused by L. tropica parasites 
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has been reported in several semi-arid hilly areas in Israel’s 
more densely populated, and less dispersed, central and 
northern population centers [10, 21].  
It is often referred to as a group of diseases because of 
the varied spectrum of clinical manifestations, which range 
from small cutaneous nodules to gross mucosal tissue de-
struction. Cutaneous leishmaniasis is the most common 
form of the disease. It usually produces ulcers on the ex-
posed parts of the body, such as the face, arms and legs [2, 
28].  The lesions typically evolve from papules to nodular 
plaques to ulcerative lesions, with a raised border and cen-
tral depression, which can be covered by scab or crust; some 
lesions persist as nodules. The lesions usually are painless 
but can be painful, especially if ulcerative lesions become 
infected with bacteria or if the lesions are near a joint. The 
healing process typically results in atrophic scarring [9]. The 
gold standard for confirmation of Leishmania infection is 
visualisation of parasites by microscopy and scrapings or 
fluid from cutaneous sores in the case of CL [23].  In cuta-
neous and mucocutaneous leishmaniasis, clinical manifes-
tations with parasitological tests confirm the diagnosis but 
serological tests have limited value [28].  The risk factors: 
poverty and malnutrition play a major role in the increased 
susceptibility to leishmaniasis.  Another risk factor is the 
movement of susceptible populations into endemic areas, 
including large-scale migration of populations for econom-
ic reasons [3]. 
Leishmania may live quietly for years in the body and 
then begin to multiply (reactivate) if the person’s immune 
system becomes suppressed. Thus, people who were born 
in a country with leishmaniasis and those who have had 
travel-related exposure are at risk if they become immuno-
suppressed by conditions such as chemotherapy, use of ster-
oids, or infection with  HIV. Patients who have previously 
had cutaneous leishmaniasis acquired in certain parts of 
the New World are at risk for mucocutaneous leishmaniasis 
[14]. Meglumine antimoniate (Glucantime) is a pentavalent 
antimony (SbV) recommended by the World Health Organi-
zation as the first-choice drug for the treatment of all types 
of leishmaniasis; the maximum dose recommended is 20 
mg/kg of body weight/day via the intramuscular route [4, 5, 
15, 25]. Some of the side-effects may be rare but serious: fe-
ver, irregular heartbeat, nausea, back pain, upper abdominal 
pain, vomiting, chills, cough, skin rash, drowsiness [18,].
Results and discussion
Patient U.V., aged 44 years, from Chisinau, was hospi-
talized in the IMSP Clinical Hospital of Infectious Diseases 
“Toma Ciorba” on 10.01.2018. At the time of admission 
there were the following complaints: physical asthenia, rash 
all over the body, skin pruritus - more pronounced in the 
eruption region. The patient is considered ill from mid-Sep-
tember 2017, when moderate skin pruritus appeared in the 
large joints, and then on the entire body surface, increasing 
in intensity until it became unbearable. On October 9-10, 
2017, there appeared skin rashes (papules) in the joints re-
gion, which then spread throughout the body. In Novem-
ber, he contacted a dermatologist who prescribed treatment 
with Betaden, Erolin, Flosteron, Ung. Dermovate, Maxitrol, 
Central -B. The indicated treatment improved the pruritus, 
but the rash continued to progress to ulceration.
On 27.12.17, the patient came to the Diagnostic Ad-
visory Center of Parasitic and Tropical Diseases of the 
Toma Ciorbă Infectious Diseases Clinical Hospital, and 
was suspected to have Leishmanioza, of skin form, which 
was later confirmed parasitologically, by detecting leishma-
nias in the smear taken from the ulcer of the left leg region 
(fig. 1) [23]. 
From the epidemiological history, it was found that dur-
ing May-June 2017 the patient was in Denmark, where he 
was bitten by mosquitoes, and from August to October 2017 
(45 days) he was in Israel, where he worked in construc-
tion, and had satisfactory living conditions in the first three 
weeks; however, afterwards, he lived in precarious condi-
tions, where there were many vagabond cats. In his spare 
time he sunbathed and swam in the sea. The patient was 
often pricked by insects, but without consequences. He also 
worked in Israel in the years 2013-2014, when he had an 
episode of hives that ceased after treatment.
At the first examination, the general condition of the pa-
tient was of average severity. He had usual skin color and 
several moist skin lesions of various sizes (1-8 cm) of pink-
burgundy color, some of which were covered with ulcera-
tions, while others were covered with crusts surrounded by 
an indented, pointed, and well-defined by a wave of edema 
and hyperemia, edge. There were also rashes characteristic 
of the first clinical manifestations of leishmaniasis and 4 pa-
pules located on the chest and abdomen. The largest lesions 
were found in the forearm and right leg 5 × 7-8 cm, on the 
face and head – rashes absented [2, 28].  In total there were 
24 eruptive outbreaks, and 3 more appeared in the first days 
of staying.
The exam on the systems did not show any special 
changes.
On 11.01.18, treatment with Meglumine antimonate 
(Glucantime) 1.5 g/5 ml – 60 mg/kg /day was initiated ac-
cording to the scheme: 1st day – 1/3 of the total dose / day 
(5 ml); day 2 – ½ of total dose / day (7.5 ml); 3rd day – ¾ – of 
total dose / day (12.5ml); 4th day total dose (15.0 ml). Sol.
Clemastin 2.0 ml i / m. Sol.Dexamethasone 4mg i / m (for 3 
days after initiation of treatment), group B vitamins.
Beginning from 21.01.18 (on the 11th day of the treat-
ment), the patient started having fever, up to 38.5 ° C, that be-
came pronounced in the second half of the day. Initially, the 
fever did not significantly affect the patient’s general condi-
tion, but, after one week, the condition gradually worsened: 
pronounced asthenia, muscle and bones pain, suffocation, 
pronounced palpitations. Data from additional investiga-
tions have excluded the association with other pathologi-
cal conditions, including sepsis, pneumonia, urinary infec-
tions, endocarditis, etc. On 29.01.18 (on the 19th day of the 
treatment), the general condition of the patient continued 
to worsen, as the signs of general intoxication have intensi-
fied, manifesting themselves through pronounced physical 
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asthenia, muscle pain, arthralgia, fever over 39.0 ° C, and 
insomnia. These symptoms were considered to be caused 
by the adverse reaction to treatment with Meglumine an-
timonate [18, 25]. Following the occurrence of these side 
effects, the dose of antimony meglumine was reduced to 5 
ml/day. On 30.01.18 the condition of the patient improved, 
the fever decreased, the signs of intoxication disappeared, 
and physical asthenia was decreasing. The patient contin-
ued treatment with Meglumine antimonate 5 ml / day un-
til 06.02.18. He was discharged on 09.02.18 in satisfactory 
condition. 1 month after the discharge, the general condi-
tion was satisfactory, and no serious consequences surfaced. 
Some crusts of very small size were present.
In fig. 2, tab. 1 and tab. 2 we present the evolution of 
cutaneous lesions and laboratory investigations during the 
treatment period:
Specific clinical data
The smear of the eruptive element from the right leg re-
gion (27.12.17) - gen. Leishmania was found.
The smear of the eruptive element from the right fore-
arm region (15.01.18) - gen. Leishmania was not found.
The smear of the eruptive element from the right later-
al abdominal region (18.01.18) - gen. Leishmania was not 
found.
Non-specific clinical data
11.01.2018 – FCC - 86 b / min; AEC – normal; sinusoi-
dal rhythm.
29.01.2018 – FCC – 110 b / min. Sinusoidal rhythm, 
tachycardia. Moderate deregulations of the ventricular re-
polarization processes in the anterolateral, apical VS region. 
Signs of overloading VS.
USG abdominal organs (11.01.2018): Liver: LD – 153 
mm; LS – 73 mm; V. Portae – 10 mm;
V. splenic – 6 mm; Gallbladder – deformed; walls – 2 
mm; calculus – absent. Pancreas – Regular contour; Struc-
ture – poorly homogeneous. Splint – 116x41mm; Ecogene-
ity – slightly increased. Kidney: Nephroptoza of grade I-II 
on the right. In the calcification system – micro-calculus 
with d = 1- 3 mm.
Conclusion USG: Hepatomegaly. The slightly increased 
ecogeneity of the liver and spleen. Deformed collector. 
Chronic pancreatitis. Renal microlithiasis, more pro-
nounced on the left, uric diathesis. Nephroptotic grade I-II 
on the right.
Flora hemoculture at sample I (31.01.18) – Aerobic flora 
– negative; Anaerobic flora – negative.
Flora Hemoculture on Sample II (05.02.18) – Aerobic 
Flora – Negative; Anaerobic flora – negative.
Table 1
Hemoleucogram in dynamics
Indicators / Data 11.01.18 15.01.18 22.01.18 27.01.18 29.01.18 30.01.18 07.02.18
Hemoglobin (g / l) 148 157 - 129 126 - -
Erythrocytes (1012/l ) 4,9 5,2↑ - 4,2 4,2 - -
Color Index 0,9 0,9 - 0,92 0,9 - -
Platelet count (109/l) 248,0 288,0 - 264,0 - - -
Leukocytes (109 / l) 6,1 12,3↑ 10,8 8,6 12,0↑ 9,8 9,8
Unsegmented (%) 15↑ 11↑ 21↑ 22↑ 7 7 8
Segmented (%) 41↓ 63 52 47 56 72 49
Eosinophils (%) 5 - 4 3 2 2 9
Lymphocytes (%) 29 19 20 25 27 15 23
Monocytes (%) 10 7 3 3 8 4 11
RSH (mm / h) 13↑ 8 - 47↑ 61↑ 49↑ 22↑
Table 2
Biochemical analysis of blood in dynamics
Indicators / Data 11.01.18 15.01.18 16.01.18 27.01.18 30.01.18 
Bilirubin mcmol / l 10,8 - - 7,6 -
ALT U/l 22,1 - - 50,7↑ 39,4
AST U/l 17,5 - - 31,6 -
Total cholesterol 
mmol/l
6,6 - - - -
Urea mmol/l 4,0 5,2 - 5,7 5,9
Creatinine mcmol/l 88,0 84,0 - 72,0 82,0
Glucose mmol/l - - 4,8 4,8 -
GGT U/l - 38,5 - 77,5 74,8
Amylase U/l 28,0 - - 58,0 -
Total protein g/l 68,9 - - - -
Prothrombin Index % 90,0 - - - -
Alkaline phosphatase U/l 163,0 - - - -
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C D
A B
Fig. 1.  Skin lesions before admission on the 08.01.2018. 
A – Right forearm, B – Right leg anterior surface, C – Left leg, D – Right leg posterior surface.
A B C
D E F
Fig. 2.  Evolution of cutaneous lesions during the treatment period.
The right forearm region on the: A – 5th day of treatment, B – 12th day of treatment, C – 23rd day of treatment.
The left leg region on the: D – 5th day of treatment, E – 12th day of treatment, F – 23rd day of treatment.
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Conclusions
1.  This case of Cutaneous Leishmaniasis is the first of 
this form registered with a national citizen returned from a 
region where the morbidity through this parasitosis varies 
from 2.7-4.5 cases in 100.000 according to literature data.
2. It is necessary to raise the level of knowledge among 
practitioners, because, due to global warming, these infec-
tions may spread through new areas linked by the presence 
of transmission vectors.
3. A thorough management is needed to highlight the 
adverse events caused by etiotropic treatment with those of 
other clinical syndromes of other origins.
4. The emergence of similar cases requires the famil-
iarization of the local medical community with the modern 
methods of diagnosis and treatment of this disease through 
continuous medical education.
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